Medscape | Positive Early-Phase Results for Ofatumumab in MS Medscape On September 25, the FDA added a boxed warning about the risk for reactivation of hepatitis B virus infection in patients who once had the virus to the product labeling for 2 drugs used for treating hematologic malignancies, ofatumumab and rituximab ... |
